Bo właściwie, to chodzi o kwestię: marichuana a zaburzenia psychiczne: leczy czy szkodzi. Poprzez system endokana. Ale, nie da się uprościć wymiarów: neuro, cog, psych, socjo. Czyli np mam takie coś: ncbi.nlm.nih.gov/pubmed/23795762 5 tysięcy artykułów reviewują i jednak, MJ koreluje ze zwiększonym występowaniem symptomów depresji, ale tu jest takie coś: ncbi.nlm.nih.gov/pubmed/14616175 " It is still too early, however, to rule out the hypothesis that the association is due to common social, family and contextual factors that increase risks of both heavy cannabis use and depression. Longitudinal studies and studies of twins discordant for heavy cannabis use and depression are needed to rule out common causes. If the relationship is causal, then on current patterns of cannabis use in the most developed societies cannabis use makes, at most, a modest contribution to the population prevalence of depression" I tu ta kwestia social. Trzeba poszperać czy da się to wzmocnić. A tacy tu: tokeofthetown/2012/01/worth_repeating_marijuana_treats_anxiety_and_depre.php "Substantial evidence has accumulated implicating a deficit in endocannabinoid in the etiology of depression; accordingly, pharmacological augmentation of endocannabinoid signaling could be a novel target for the pharmacotherapy of depression." "Within preclinical models, facilitation of endocannabinoid neurotransmission evokes both antidepressant and anxiolytic effects. Similar to the actions of conventional antidepressants, enhancement of endocannabinoid signaling can enhance serotonergic and noradrenergic transmission; increase cellular plasticity and neurotrophin expression (brain growth factor) within the hippocampus; and dampen activity within the neuroendocrine stress axis." "Furthermore, limbic endocannabinoid activity is increased by both pharmacological and somatic treatments for depression, and, in turn, appears to contribute to some of the neuroadaptive alterations elicited by these treatments." (Read = cannabinoids heal the brain) "These preclinical findings support the rationale for the clinical development of agents which inhibit the cellular uptake and/or metabolism of endocannabinoids in the treatment of mood disorders." to choć od badaczy ustanowionych, to jednak na pewno niszowa hipoteza
Posted on: Fri, 09 Aug 2013 22:41:11 +0000
Trending Topics
Recently Viewed Topics
© 2015